Geode Capital Management LLC Has $1.73 Billion Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Geode Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,427,630 shares of the biopharmaceutical company's stock after acquiring an additional 155,369 shares during the quarter. Geode Capital Management LLC owned 2.21% of Regeneron Pharmaceuticals worth $1,726,940,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Norges Bank bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $802,036,000. Amundi grew its position in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Loomis Sayles & Co. L P increased its holdings in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after purchasing an additional 393,997 shares in the last quarter. Proficio Capital Partners LLC raised its position in Regeneron Pharmaceuticals by 92,865.3% in the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after purchasing an additional 219,162 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in Regeneron Pharmaceuticals by 7.9% in the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after purchasing an additional 149,124 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Analyst Ratings Changes

REGN has been the subject of a number of research reports. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research note on Monday. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Piper Sandler lowered their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Finally, Bank of America reaffirmed an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $966.88.

Regeneron Pharmaceuticals Trading Down 2.4 %

Shares of Regeneron Pharmaceuticals stock traded down $14.96 during trading hours on Thursday, hitting $610.64. The company's stock had a trading volume of 1,047,509 shares, compared to its average volume of 682,138. Regeneron Pharmaceuticals, Inc. has a 12 month low of $605.56 and a 12 month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market capitalization of $66.76 billion, a PE ratio of 15.95, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The stock has a 50 day moving average of $678.75 and a 200 day moving average of $785.70.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the prior year, the business earned $11.86 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.